We constructed LL2 lung cancer subcutaneous model and H460 NSCLC xenograft model in mice to evaluate combinational therapy outcomes of JDB153 plus immunotherapy (PD‐1 Ab) and chemotherapy (cisplatin) respectively. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.